• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

应用时滞微分方程和主成分分析研究胃排空对药代动力学参数的影响。

Investigating the Impact of Gastric Emptying on Pharmacokinetic Parameters Using Delay Differential Equations and Principal Component Analysis.

机构信息

Laboratory of Biopharmaceutics, Pharmacokinetics, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15784, Athens, Greece.

Institute of Applied and Computational Mathematics (IACM)/Foundation of Research and Technology Hellas (FORTH), Heraklion, Crete, Greece.

出版信息

Eur J Drug Metab Pharmacokinet. 2021 May;46(3):451-458. doi: 10.1007/s13318-021-00683-3.

DOI:10.1007/s13318-021-00683-3
PMID:33768449
Abstract

BACKGROUND AND OBJECTIVES

Losartan presents multiple peaks after single oral administration, which can be attributed to gastric emptying. The aim of this study was to describe the multiple peak phenomenon of losartan using a delay differential model and a model with sine function. The impact of gastric emptying on pharmacokinetic parameters was investigated by applying principal component analysis to the individual parameter estimates.

METHODS

Using Monolix, two population pharmacokinetic models were developed to describe the multiple peak phenomenon; the first using delay differential equations and the second using a sine function. Matlab delay differential equation solver was used to arithmetically solve both functions. Principal component analysis and all statistical analyses were performed in the R language.

RESULTS

The description of losartan multiple peaks can be achieved by the use of either delay differential equations or typical sine wave functions. Principal component analysis unveiled the impact of gastric emptying on the pharmacokinetic parameters. In the case of the delay differential equation model, a negative relationship was found between the constant delay tau1 and the parameters reflecting rate and extent of absorption (i.e., area under the curve [AUC], peak plasma concentration [C], and the absorption rate constant). Similar results were obtained from the sine model, where a higher amplitude and lower period (i.e., higher frequency) of gastric emptying were associated with higher AUC and C values.

CONCLUSIONS

The observed multiple peaks for certain drugs like losartan can be attributed to gastric emptying. Parameters describing gastric emptying can be associated with pharmacokinetic metrics like AUC and C.

摘要

背景与目的

氯沙坦经单次口服后呈现多重峰,这归因于胃排空。本研究旨在使用延迟微分模型和正弦函数模型来描述氯沙坦的多重峰现象。通过对个体参数估计进行主成分分析,研究了胃排空对药代动力学参数的影响。

方法

使用 Monolix,建立了两个群体药代动力学模型来描述氯沙坦的多重峰现象;第一个模型使用延迟微分方程,第二个模型使用正弦函数。使用 Matlab 延迟微分方程求解器对这两个函数进行了数值求解。主成分分析和所有统计分析均在 R 语言中进行。

结果

可以使用延迟微分方程或典型的正弦波函数来描述氯沙坦的多重峰。主成分分析揭示了胃排空对药代动力学参数的影响。在延迟微分方程模型中,发现常数延迟 tau1 与反映吸收速率和程度的参数(即曲线下面积 [AUC]、血浆峰浓度 [C] 和吸收速率常数)呈负相关。在正弦模型中也得到了类似的结果,其中胃排空的更高振幅和更低周期(即更高频率)与更高的 AUC 和 C 值相关。

结论

某些药物(如氯沙坦)出现的多重峰可以归因于胃排空。描述胃排空的参数可以与 AUC 和 C 等药代动力学指标相关联。

相似文献

1
Investigating the Impact of Gastric Emptying on Pharmacokinetic Parameters Using Delay Differential Equations and Principal Component Analysis.应用时滞微分方程和主成分分析研究胃排空对药代动力学参数的影响。
Eur J Drug Metab Pharmacokinet. 2021 May;46(3):451-458. doi: 10.1007/s13318-021-00683-3.
2
Modelling gastric emptying: A pharmacokinetic model simultaneously describing distribution of losartan and its active metabolite EXP-3174.胃排空建模:同时描述洛沙坦及其活性代谢物 EXP-3174 分布的药代动力学模型。
Basic Clin Pharmacol Toxicol. 2020 Mar;126(3):193-202. doi: 10.1111/bcpt.13321. Epub 2019 Oct 7.
3
Empirical and semi-mechanistic modelling of double-peaked pharmacokinetic profile phenomenon due to gastric emptying.基于胃排空的双峰药代动力学特征现象的经验性和半机制建模
AAPS J. 2015 Jan;17(1):227-36. doi: 10.1208/s12248-014-9693-5. Epub 2014 Nov 21.
4
Delay differential equations for the description of Irbesartan pharmacokinetics: A population approach to model absorption complexities leading to dual peaks.用于描述厄贝沙坦药代动力学的延迟微分方程:一种采用群体方法对导致双峰的吸收复杂性进行建模。
Eur J Pharm Sci. 2020 Oct 1;153:105498. doi: 10.1016/j.ejps.2020.105498. Epub 2020 Jul 29.
5
Delayed postoperative gastric emptying following intrathecal morphine and intrathecal bupivacaine.鞘内注射吗啡和鞘内注射布比卡因后延迟性术后胃排空
Can J Anaesth. 1999 Jun;46(6):544-9. doi: 10.1007/BF03013544.
6
Application of the GastroDuo to study the interplay of drug release and gastric emptying in case of immediate release Aspirin formulations.应用 GastroDuo 研究速释阿司匹林制剂中药物释放和胃排空的相互作用。
Eur J Pharm Biopharm. 2020 Jun;151:9-17. doi: 10.1016/j.ejpb.2020.03.013. Epub 2020 Apr 5.
7
Variable gastric emptying and discontinuities in drug absorption profiles: dependence of rates and extent of cimetidine absorption on motility phase and pH.胃排空可变及药物吸收曲线的不连续性:西咪替丁吸收速率和程度对运动期及pH的依赖性。
Biopharm Drug Dispos. 1994 Dec;15(9):719-46. doi: 10.1002/bdd.2510150902.
8
The rate of gastric emptying determines the timing but not the extent of oral tacrolimus absorption: simultaneous measurement of drug exposure and gastric emptying by carbon-14-octanoic acid breath test in stable renal allograft recipients.胃排空速率决定口服他克莫司吸收的时间,但不决定吸收程度:通过碳-14-辛酸呼气试验对稳定的肾移植受者同时测量药物暴露量和胃排空情况。
Drug Metab Dispos. 2004 Dec;32(12):1421-5. doi: 10.1124/dmd.104.001503. Epub 2004 Sep 21.
9
Gastric emptying in patients with insulin dependent diabetes mellitus and bioavailability of thioctic acid-enantiomers.胰岛素依赖型糖尿病患者的胃排空及硫辛酸对映体的生物利用度
Eur J Pharm Sci. 1998 Jan;6(1):27-37. doi: 10.1016/s0928-0987(97)00065-1.
10
Structural identifiability analysis of pharmacokinetic models using DAISY: semi-mechanistic gastric emptying models for 13C-octanoic acid.使用 DAISY 进行药代动力学模型的结构可识别性分析:13C-辛酸的半机理胃排空模型。
J Pharmacokinet Pharmacodyn. 2011 Apr;38(2):279-92. doi: 10.1007/s10928-011-9193-5. Epub 2011 Feb 24.

本文引用的文献

1
Modelling gastric emptying: A pharmacokinetic model simultaneously describing distribution of losartan and its active metabolite EXP-3174.胃排空建模:同时描述洛沙坦及其活性代谢物 EXP-3174 分布的药代动力学模型。
Basic Clin Pharmacol Toxicol. 2020 Mar;126(3):193-202. doi: 10.1111/bcpt.13321. Epub 2019 Oct 7.
2
On the population pharmacokinetics and the enterohepatic recirculation of total ezetimibe.关于依折麦布总量的群体药代动力学及肠肝循环
Xenobiotica. 2019 Apr;49(4):446-456. doi: 10.1080/00498254.2018.1463117. Epub 2018 Apr 27.
3
Gastrointestinal Motility Variation and Implications for Plasma Level Variation: Oral Drug Products.
胃肠动力变化及其对血浆水平变化的影响:口服药品
Mol Pharm. 2016 Feb 1;13(2):557-67. doi: 10.1021/acs.molpharmaceut.5b00774. Epub 2016 Jan 7.
4
Analysis of Intra- and Intersubject Variability in Oral Drug Absorption in Human Bioequivalence Studies of 113 Generic Products.113种仿制药人体生物等效性研究中口服药物吸收的个体内和个体间变异性分析。
Mol Pharm. 2015 Dec 7;12(12):4405-13. doi: 10.1021/acs.molpharmaceut.5b00602. Epub 2015 Nov 20.
5
The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.生物药剂学分类系统:体内预测溶出度(IPD)方法和体外-体内相关性的子类。
Eur J Pharm Sci. 2014 Jun 16;57:152-63. doi: 10.1016/j.ejps.2014.01.009. Epub 2014 Jan 28.
6
Multiple peaking phenomena in pharmacokinetic disposition.药代动力学处置中的多重峰现象。
Clin Pharmacokinet. 2010 Jun;49(6):351-77. doi: 10.2165/11319320-000000000-00000.
7
Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation.氯沙坦的长期治疗可使代谢产物EXP3179的血清水平达到足以激活PPARγ的程度。
Hypertension. 2009 Oct;54(4):738-43. doi: 10.1161/HYPERTENSIONAHA.109.132886. Epub 2009 Aug 17.
8
Clinical pharmacokinetics of losartan.氯沙坦的临床药代动力学
Clin Pharmacokinet. 2005;44(8):797-814. doi: 10.2165/00003088-200544080-00003.
9
Comparative pharmacokinetics of two tablet formulations of Losartan: bioequivalence assessment.氯沙坦两种片剂剂型的比较药代动力学:生物等效性评估。
Biopharm Drug Dispos. 2005 Jul;26(5):205-10. doi: 10.1002/bdd.448.
10
The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog.血管紧张素II受体拮抗剂氯沙坦钾(DuP 753/MK 954)在犬体内的药代动力学和药效学
J Pharmacol Exp Ther. 1994 Mar;268(3):1199-205.